[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@drughunter_com Avatar @drughunter_com drug hunter

drug hunter posts on X about approved, novartis, china, $8604t the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks countries

Social topic influence approved, novartis #19, china, $8604t, deep learning, $ptct, eli lilly, breast cancer, dmg

Top assets mentioned Novartis AG (NVS) PTC Therapeutics, Inc. (PTCT) Eli Lilly and Company (LLY)

Top Social Posts #

Top posts by engagements in the last XX hours

"Fulzerasib: A Structure-guided Cyclic Analog of Sotorasib Approved in China for nSCLC Fulzerasib is a covalent KRAS(G12C) inhibitor developed based on structural analysis of the FDA-approved inhibitor sotorasib. The resulting novel series was optimized for potency and selectivity permeability GSH stability PK and CYP3A4 inhibition. Fulzerasib was approved in China in 2024 to treat non-small cell lung cancer in patients harboring the KRAS(G12C) mutation and studies are ongoing in the search for FDA approval. Read it on Drug Hunter"
X Link @drughunter_com 2025-10-07T15:10Z 10.7K followers, 1517 engagements

"More than XX% of human proteins are still considered undruggable because they lack known or well-defined binding pockets that can be effectively targeted by small molecules. In this Flash Talk Daniel Nomura Professor of Chemical Biology and Molecular Therapeutics will present his groups recent efforts applying chemoproteomic approaches to identify and pharmacologically target novel ligandable hotspots within disease-relevant proteins. Daniel will also highlight how chemoproteomic platforms have expanded the scope of emerging therapeutic modalities including targeted protein degradation and"
X Link @drughunter_com 2025-10-13T20:33Z 10.7K followers, 1485 engagements

"In this Flash Talk Peter Skewes-Cox presented recent AI-driven advances in high-content screening that are accelerating drug discovery by augmenting and even replacing traditional workflows. Peter emphasized that while HCS once depended on manual processing deep learning methods now allow for a higher degree of automation. Inspired by innovations in natural image classification and autonomous driving AI methods have significantly advanced cellular image interpretation. Generative AI approaches including in silico labeling and profile-conditioned diffusion further extend these capabilities."
X Link @drughunter_com 2025-10-13T15:03Z 10.7K followers, 1139 engagements

"Votoplam: A CNS-Penetrant HTT pre-mRNA Splice Modulator for the Treatment of Huntingtons Disease Votoplam (PTC518) is an HTT pre-mRNA splice modulator originally developed by PTC Therapeutics and later in-licensed by Novartis currently being evaluated in a Ph. X clinical trial for the treatment of Huntingtons disease. A pioneer in mRNA-targeting small molecules PTC leveraged its splicing platform to discover an orally bioavailable compound capable of lowering levels of mHTT the key driver of HD pathogenesis. Votoplam promotes the inclusion of a pseudoexon in the mHTT mRNA transcript that"
X Link @drughunter_com 2025-10-03T20:33Z 10.7K followers, 2097 engagements

"The second of a two-part review on CDK4/6 inhibitors focuses on the approved molecules that transformed the treatment of HR+/HER2- breast cancer. Palbociclib (Pfizer) ribociclib (Novartis) and abemaciclib (Eli Lilly) have shown a significant extension in progression-free survival when combined with endocrine therapy. Though all three share a common ATP-competitive binding motif their divergent chemotypes lead to differences in selectivity and tolerability. - palbociclib was the first CDK4/6 inhibitor approved and was optimized for CDK4/6 selectivity - ribociclib achieved 10000 fold"
X Link @drughunter_com 2025-10-15T20:54Z 10.7K followers, 1058 engagements

"Dordaviprone received FDA accelerated approval for the treatment of DMG (diffuse midline glioma) harboring the H3(K27M) mutation in patients X year old with progressive disease after prior therapy. It is the first FDA-approved systemic therapy specifically for H3(K27M)mutant DMGa disease that primarily affects children and young adultsand the first imipridone from the @Chimerix/@JazzPharma partnership to reach approval. Read more:"
X Link @drughunter_com 2025-10-11T15:08Z 10.7K followers, 3390 engagements